Impact of Anti-Xa-Guided Individualized Anticoagulation on VET Parameters of Hemostasis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037385

Enrollment

Registered

2025-07-10

Start date

2025-07-21

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A41.9 I80.9

Interventions

Group 1: Patients receiving low-molecular-weight heparin (LMWH) and diagnosed with sepsis. Blood sampling was performed at the time of peak plasma concentration

analyses included viscoelastic testing (VET) and additional paraclinical coagulation function parameters. Group 2: Patients receiving low-molecular-weight heparin (LMWH) without sepsis. Blood sampling

analyses included viscoelastic testing (VET) and additional paraclinical coagulation function parameters. Group 3: Patients receiving unfractionated heparin (UFH) and diagnosed with sepsis. Blood samp

analyses included viscoelastic testing (VET) and additional paraclinical coagulation function parameter Group 4: Patients receiving unfractionated heparin (UFH) without sepsis. Blood sampling was perf

analyses included viscoelastic testing (VET) and additional paraclinical coagulation function parameters.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Treatment with anticoagulant medication (UFH, LMWH, or Argatroban) at any dosage.

Exclusion criteria

Exclusion criteria: - Known hereditary coagulation disorder - Missing indication or contraindications for anticoagulation

Design outcomes

Primary

Measure	Time frame
The primary aim of the study is to investigate the impact of Anti-Xa-guided individualized anticoagulation on viscoelastic coagulation measurements in critically ill patients.	—

Secondary

Measure	Time frame
As a secondary objective, the study aims to evaluate to what extent the Anti-Xa level reliably reflects the patients’ global coagulation status.	—

Countries

Germany

Contacts

Public ContactMartin Mirus

Universitätsklinikum Carl Gustav Carus Dresden, TU Dresden, Klinik für Anästhesiologie und Intensivtherapie

martin.mirus@ukdd.dde+49 351 458 19382

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026